|Publication number||US3923939 A|
|Publication date||2 Dec 1975|
|Filing date||7 Jun 1974|
|Priority date||7 Jun 1974|
|Also published as||CA1047403A, CA1047403A1, DE2525061A1, DE2525061C2|
|Publication number||US 3923939 A, US 3923939A, US-A-3923939, US3923939 A, US3923939A|
|Inventors||Baker Richard W, Michaels Alan S, Theeuwes Felix|
|Original Assignee||Alza Corp|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (2), Referenced by (85), Classifications (23)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent Baker et al.
Dec. 2, 1975 PROCESS FOR IMPROVING RELEASE KINETICS OF A MONOLlTHlC DRUG DELIVERY DEVICE  Inventors: Richard W. Baker, Mountain View;
Alan S. Michaels, Atherton; Felix 'lheeuwes, Los Altos, all of Calif.
 Assignee: Alza Corporation, Palo Alto, Calif.
 Filed: June 7, 1974  Appl. No.: 477,297
I52] US. Cl. 264/49; 264/109; 264/233;
 Int. Cl. B29D 27/00  Field of Search 264/233, 344, 49, 10);
 References Cited UNITED STATES PATENTS 3,402,240 9/1968 Cain et al. 424/22 3,700,380 l0/l972 Kitrilakis 264/49 UX R27,l07 3/1971 Levesque 424/22 FOREIGN PATENTS OR APPLICATIONS 808,014 1/1959 United Kingdom 424/22 Primary E.\'aminerPhilip Anderson Atl0rn0y,Agenl, 0r FirmThomas E. Ciotti; Paul L. Sabatine; Edward L. Mandell  ABSTRACT A process for improving the release kinetics of a monolithic active agent delivery device comprising a shaped body of a dispersion of particulate active agent, such as a drug, with a polymer matrix, such as ethylene/vinylacetate copolymer, by substantially reducing the initial burst of active agent from the device when it is placed in its'cnvironment of use. The process involves prior to placing the body in its use environment removing, such as by water washing, the par ticulate drug from the exterior surface of the body to form an agent depleted layer of polymer matrix voided by the removal of the agent, the thickness of the layer being at least 571 of the overall body thickness.
14 Claims, 10 Drawing Figures US. Patent Dec. 2. 1975 Sheet of} 3,923,939
DEVICE 0F EXAMPLE IA TIME (DAYS) Dec. 2, 1975 shw 2 0f 3 3,923,939
DEVICESOF EXAMPLE IB 0.04? CM. do 560 US. Patent 600 760 800 TIME (DAYS TIME (DAYS) DEVICESOF EXAMPLE 2A E DEVICES 0F EXAMPLE 2B 0 4'00 TIM E (ms) US. Patent Dec. 2, 1975 DEVICE 0F EXAMPLE 3A 0 (m /HOUR) PILOCAPIRE RELEASE RATE TIME (HOURS) Sheet 3 of 3 PIL QCAPINE RELEASE RATE (mcg/ HOUR) DEVICES OFEXAMPLE TIME (HOURS) PROCESS FOR IMPROVING RELEASE KINETICS OF A MONOLITI-IIC DRUG DELIVERY DEVICE BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to a process for improving the active agent release kinetics of a monolithic active agent delivery device.
2. Description of the Prior Art Monolithic devices for sustainedly releasing drugs or other active agents are well known in the art. One type of monolithic device consists of a shaped body of particulate, usually solid, drug dispersed uniformly in a polymer matrix permeable to the drug by diffusion. The polymer matrix may be substantially imperforate and homogeneous in which case the drug dissolves in and permeates through the polymer material itself. Alternatively, the matrix may be microporous, the pores of which contain a drug-permeable liquid or gel medium, in which case the drug will preferentially dissolve in and permeate through the medium in the pores. It is of course possible to use a polymer matrix which is both microporous and made of a polymer permeable to the drug in which case movement of the drug through the matrix is via a combination of the above described modes.
Another type of monolithic device for use in releasing active agents into aqueous environments, such as drugs into the various cavities of the human body, consists of a shaped body of discrete particulate osmotic solute/active agent depots dispersed in and surrounded by an active agent impermeable but water permeable polymer matrix whose cohesive strength is exceeded by the osmotic pressure generating ability of the individual depots. Such devices release their active agent by an osmotic bursting mechanism in which water is imbibed osmotically into the depots nearest the exterior surfaces of the device, thereby dissolving those depots contents and generating pressure therewithin sufficient to cause the surrounding polymer matrix to rupture thus allowing release of the agent therefrom and access by the environment to the next nearest depots and serially so forth. These monolithic osmotic bursting" devices are the subject matter of commonly assigned, copending application Ser. No. 354,359 filed Apr. 25, 1973 and now abandoned, the disclosure of which is incorporated by reference herein.
These monolithic devices are attractive commercially because they are inexpensive and easily fabricated relative to other devices such as laminated devices or capsule devices. Also, in the case of some drugs, a monolithic device is the only type of device capable of practically and sustainedly releasing the drug at a therapeutically effective rate.
The active agent release kinetics of these monolithic devices exhibit a feature which is often undesirable, namely the release begins at a high rate--called an initial burst-which rapidly decreases to a significantly lower rate. The kinetics of monolithic diffusion for a device having a thin rectangular cross sectional shape (i.e., the device is shaped as a flat slab) may be expressed by the equation:
(dMJd!) A (DC, C.,/2 in which M, is the agent released at time, t, C is the agent solubility in the polymer matrix, C, is the total concentration of agent in the polymer matrix, C, being and a sphere are also known T. Higuchi, J. Pharm. Soil, 50, 874 (196i).
T. J. Roseman et al.. J. Pharm. SCI., 59. 353 (1970); T. J. Roseman, J. Pharm. Sci., 6i, 46 (1972); and H. K. Lonsdale, R. W. Baker, Controlled Release of Biologically Active Agents", Ed. C. Tanquery, Plenum Press, New York (1974).
In a plot of the above equation with dMJdt plotted against 1, the release rate in the initial stage of release is extremely high and drops off very quickly to a level markedly below the rate in the initial stage. Corresponding plots for monolithic diffusion devices of other simple geometry, such as a rod-like cylinder or sphere, follow the same general release rate pattern as the simple slab described above.
The release kinetics for monolithic osmotic bursting devices have been found empirically to also exhibit an initial burst which decreases rapidly to a significantly lower rate. However the release rate plateaus after the initial decrease in the osmotic bursting devices whereas it continuously decreases in the diffusion devices.
In both types of devices this initial burst of active agent may be undesirable because it results in overdosing, toxicity or side reactions, or may not conform to the optimal dosage regimen for a particular active agent.
The initial high level or burst in the release rate of active agent from a monolithic device may be reduced by coating the body with a layer of pure polymer ma trix. Such a coated device is taught (the coating is used for a different purpose) in US. Pat. No. 3,577,512 issued May 4, 1971 to T. H. Shepherd et al. However this coating procedure has the disadvantage of lowering the entire release rate profile (i.e., the entire dM /dt vs. 2 plot) of the device. Such lowering may result in release rates below those required for efficacy. Also, if the device has an irregular shape, it is usually quite difficult to devise a manufacturing procedure to make a continuous, uniform coating on the device in a reproducible manner.
SUMMARY OF THE INVENTION This invention is a process for improving the release kinetics of the above described monolithic active agent delivery devices by substantially eliminating the initial burst of active agent release without significantly lowering the entire release rate profile of the device. This novel process comprises, prior to placing the device in its intended environment of use, removing the particulate agent from the exterior surface of the device to form an agent depleted layer of polymer matrix voided by the removal of the particulate agent.
In a preferred embodiment of this process the removal of particulate agent from the surface of the device is done by washing the device in a liquid which does not deleteriously affect the polymer matrix at a temperature which enhances the removal of agent from the matrix.
The devices made by the invention process are placed in fluid containing environments into which the agent is released by diffusion or by osmotic bursting. Depending on the particular active agent involved the environment may be a body cavity, a stream, an aquarium, soil, a chemical reactor or the like. Embodiments intended to release drug within body cavities may be placed within the gastrointestinal tract, mouth, eye,
uterus, vagina and other cavities.
BRIEF DESCRIPTION OF THE DRAWINGS In the drawings:
FIG. 1 is a vertical, sectional view of a disc-shaped monolithic diffusion type drug delivery device made in accordance with the invention process;
FIG. 2 is an enlarged view of a portion of the section of FIG. 1 taken along line 2-2 of FIG. 1;
FIG. 3 is a graphic representation of the release kinetics of a prior art monolithic diffusion drug delivery device;
FIG. 4 is a graphic representation of the improvements in the release kinetics of the device represented in FIG. 3 which may be realized by subjecting that device to the process of this invention;
FIG. 5 is a graphic representation of several prior art devices of the same geometry as the device of FIG. 3 but having different loadings of active agent; and
FIG. 6 is a graphic representation of the improvements in the release kinetics of the devices of FIG. 5 which may be realized by subjecting those devices to the process of this invention;
FIG. 7 is a vertical, sectional view of a disc-shaped monolithic osmotic bursting drug delivery device made by the invention process;
FIG. 8 is an enlarged view of a portion of a section of FIG. 7 taken along line 8-8 of FIG. 7;
FIG. 9 is a graphic representation of the release kinetics of a prior art monolithic osmotic bursting drug delivery device; and
FIG. 10 is a graphic representation of the improvement in the release kinetics of the device of FIG. 9 which may be realized by treating that device in accordance with the process of this invention.
DETAILED DESCRIPTION OF THE INVENTION FIG. 1 depicts a disc-shaped monolithic diffusion type active agent delivery device, generally designated 10, comprising a particulate active agent 11, such as drug, dispersed in a polymer matrix 12. The particles of agent 11 may be liquid, semi-solid or solid but are preferably solid.
Active agents as used herein include those compositions of matter which when dispensed in their environment of use produce a predetermined, beneficial and useful result. Such agents include for example pesticides, herbicides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, anti-oxidants, plant growth promotors and inhibitors, preservatives, surfactants, disinfectants, catalysts, fermentation agents, nutrients, drugs, plant minerals, sex sterilants, plant hormones, air purifiers, micro-organism attenuators and the like.
Drug as used herein broadly includes physiologically or pharmacologically active substances for producing a localized effect at the administration site or a systemic effect at a site remote from the administration site. Such drugs include inorganic and organic compounds, for example, drugs which act on the central nervous system such as hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants, muscle relaxants and anti-parkinson agents, antipyretics and anti-inflammatory agents, local anesthetics, anti-spasmodics and antiulcer agents, prostaglandins, antimicrobials, hormonal agents, estrogenic steroids, progestational steroids, such as for contraceptive purposes, sympathomimetic drugs, cardiovascular drugs,
4 diuretics, antiparasitic agents, hypoglycemic drugs and ophthalmic drugs.
In the osmotic bursting devices the active agent must either itself be water soluble to the extent that the osmotic pressure of a saturated solution thereof exceeds the osmotic pressure of the external environment of use or it must be mixed with a compatible osmotically effective solute such as an inorganic or organic salt capable of generating such an osmotic pressure. Such pressure provides the necessary driving force by which the osmotic bursting mechanism is effected. Methods of calculating or measuring osmotic pressure are well known. See for example, S. Glasstone, Textbook of Physical Chemistry, MacMillan & Co., London (1960).
As indicated above, in the monolithic diffusion devices the polymer forming the polymer matrix may be substantially imperforate and homogeneous or microporous. Examples of substantially imperforate polymers which may be used are poly(methylmethacrylate), poly(butylmethacrylate), plasticized poly(vinylchloride), plasticized soft nylon, natural rubber, poly(isoprene), poly(isobutylene), poly(butadiene), poly(ethylene), poly(vinylidene chloride), cross-linked poly(vinylpyrrolidone), chlorinated poly(ethylene) poly(4,4-isopropylidene diphenylene carbonate), ethylene-vinylacetate copolymer, plasticized ethylene-vinylacetate copolymer, vinylidene chloride-acrylonitrile copolymer, vinyl chloride-diethyl fumerate copolymer, silicone rubbers, especially the medical grade poly(- dimethylsiloxanes), ethylene-propylene rubber, silicone-carbonate copolymers, vinylidene chloride-vinyl chloride copolymer, vinyl chloride-acrylonitrile copolymer and vinylidene chloride-acrylonitrile copolymer.
Microporous materials which may be used in making monolithic devices have pores which range in size from at least about IOA to several hundred microns, but usually not more than about I00 microns. Examples of materials from which microporous structures may be made are regenerated, insoluble, nonerodible cellulose, acylated cellulose, esterified cellulose, cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose acetate diethylamino-acetate, poly(urethanes), poly(carbonates), modified insoluble collagen, cross-linked poly(vinyl alcohol), epoxy resins and poly(olefins) or poly(vinylchlorides). These materials may be made microporous by well known procedures such as coprecipitation or leaching out incorporated salts, soap micelles, starch or like materials. See, for example, J. D. Ferry, Chemical Reviews, 18, 373 (I935).
Diffusive media which may be used to fill the pores of the porous materials should be compatible with the environment of use. Also the active agent should leave only limited solubility in the medium (10 ppm to 10,000 ppm on a weight basis) so that the active agent is released by diffusion rather than by simple dissolutron.
Representative media are saline, glycerin, ethylene glycol, propylene glycol, water, emulsifying and suspending agents such as methyl cellulose mixed with water, mixtures of propylene glycol monostearate and oils, gum tragacanth, sodium alginate, poly(vinyl pyrrolidone), poly(oxyethylene stearate), fatty acids such as linoleic, and silicone oil. Other representative media are set forth in Remingtons Pharmaceutical Sciences, pages 24 to 269 and 1338 to 1380, 1970, published by Mack Publishing Co., Easton, Pas.
The polymers used to make the osmotic bursting devices may be defined in terms of their permeabilities to active agent and water and their tensile strength and maximum elongation (which delimit their cohesive and rupture strength). Normally these materials will have water permeabilities of about g m "1 -24 hr- 100% rel. humidity a tensile strength of about 14 to 700 kg/cm (preferably 35 to 210 kglcm and a maximum elongation of IO% to 2000% (preferably 200% to l700%). They also should'have a high degree of impermeability to the active agent i.e., active agent permeabilities less than cm /sec.
Typical polymers for forming the osmotic bursting devices include unplasticized cellulose acetate, cellulose nitrate with 1 1% nitrogen, cellulose diacetate, cellulose triacetate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, cellulose acetate, acetaldehyde dimethyl acetate, cellulose acetate ethyl carbamate, cellulose acetate phthalate, cellulose acetate methyl carbamate, cellulose acetate succinate, cellulose acetate dimethaminoacetate, cellulose acetate ethyl carbonate, cellulose acetate chloroacetate, cellulose acetate ethyl oxatate, cellulose acetate methyl sulfonate, cellulose acetate butyl sulfonate, cellulose acetate propionate, cellulose acetate butyl sulfonate, cellulose acetate propionate, cellulose acetate p-toluene sulfonate, triacetate of locust gum bean, cellulose acetate with acetylated hydroxy-ethyl cellulose, hydroxylated and unhydroxylated ethylene-vinyl acetate copolymers, highly plasticized polyvinyl chloride, homoand copolymers of polyvinyl acetate, polymers of acrylic acid and methacrylic acid, polyvinyl alkyl ethers, polyvinyl fluoride, polycarbonates, polymeric epoxides, copolymers of an alkylene oxide and alkyl glycidyl ether, semi-permeable polyurethanes, semipermeable polyglycolic or polylactic acid and derivatives thereof and derivatives of polystyrene such as poly(sodium styrenesulfonate) and poly(vinylbenzyl trimethylammonium chloride). Ethylene-vinyl acetate copolymers, either alone or mixed with other materials, are especially useful for forming the osmotic bursting device. Preferred among the ethylene-vinyl acetate copolymers are those having a melt index above about g/min and a vinyl acetate content above about 20%, such as from 20-45%.
In the diffusion devices the concentration of active agent dispersed in the polymer matrix will primarily depend upon the desired dosage level for the device. Normally the concentration of active agent will be in the range of 5 to 70 weight percent based on the polymer matrix. Its particle size will usually be in the range of 0.1 to 100 microns.
In the osmotic bursting devices the active agent depot loading (which depends on the size and number of depots percent volume) is important. The depots will usually comprise 5% to 70% by weight of the device. In this range sufficient polymer is present to adequately encapsulate the depots and maintain the devices integrity after a substantial amount of the agent depots have been released. The depot size will usually range between 0.l and 100 microns in diameter.
The shape of the device made from the above described active agent/polymer dispersions will depend on the intended environment of use. In most environments complex shapes will be unnecessary and thus for convenience and economy the device will have a sim ple shape such as flat disc, a cylindrical rod, or a sphere. For specific embodiments such as an embodiment intended for use in the eye to release an ophthalmic drug therein, the device will usually be in the shape of a flat disc, oval, ellipse or kidney.
The device will be sized according to the environment and desired dosage. Drug delivery devices for implanting in the body will be sized in accordance with the dimensions of the implant size. For instance for ocular inserts for inserting in a cul-de-sac of the eye the device will normally have a length of 4 to 20 mm, a width of l to 15 mm and a thickness of 0.1 to 4 mm and will usually contain 1 to 200 mg ophthalmic drug.
The active agent/polymer dispersions may be formed by mixing the two components by conventional techniques. Likewise, the dispersions may be formed into shaped bodies by conventional techniques such as solvent casting, extruding, roll milling, melt pressing, cutting, punching and the like.
After the dispersion is formed into the desired shape (this may be its final form for introducing into the use environment or some intermediate form such as a large sheet or roll) but before it is placed in the environment of use, the particles of active agent are removed from the exterior surface layer of the body in accordance with the process of this invention. This may be done by washing the body with a liquid which is inert relative to the polymer matrix (in other words the liquid should not deleteriously affect the polymer matrix either physically or chemically such as by dissolving, disintegrating, or chemically reacting with the matrix). For convenience and economy the wash liquid will usually be aqueous, with water being preferred.
In a diffusion device the washing of the device causes active agent which is dissolved in the polymer matrix at the surface to diffuse into the wash liquid which in turn causes agent particles located at or nearthe surface to dissolve into the polymer and be diffused therefrom. In the case of the osmotic bursting devices the washing causes any agent at the surface to be dissolved and water to be imbibed by the encapsulated agent depots causing them to burst and release their contents. In both types of devices this washing ultimately results in the active agent being depleted from a surface layer of desired thickness. In the device shown in FIGS. 1 and 2 the drug has been depleted from a layer, designated A, at the exterior surface of the device leaving voids 14. The number and size of the voids in the matrix will depend on the concentration and particle size of the dispersed active agent. In this regard it has been observed that the voids tend to irreversibly shrink, i.e., the porosity of the layer decreases, if the device is permitted to dry after the washing. This phenomenon is believed to make the layer of a dried device act more like a coating of pure matrix in that it may be less permeable to the agent than the remainder of the matrix. In any event voids l4 affect the release kinetics of device 10 because they form preferred pathways (indicated by small arrows) for the active agent to diffuse along.
FIGS. 7 and 8 illustrate a monolithic osmotic bursting active agent delivery device, generally designated 15, which has been prewashed in accordance with the invention process. Device 15 comprises discrete active agent/osmotic solute depots l6 encapsulated within a polymer matrix 17. As shown in FIG. 8 the prewashing 7 has depleted the active agent depots from a layer, designated B, at the surface of the device leaving voids l8. Voids 18 are similar to voids 14 of device 10 except that voids 18 are substantially interconnected due to the bursting mechanism by which the active agent was released.
The process conditions of the wash, e.g., time and temperature, will be selected to provide an agent depleted layer of predetermined thickness. Given a desired layer thickness the wash temperature and time will depend on the particular polymer and active agent involved. In a diffusion device wash times may be shortened by employing temperatures at which diffusion is enhanced. In an osmotic bursting device wash times may be shortened by using temperatures at which water inhibition by the depots is enhanced. In almost all instances this means that elevated temperatures (above ambient temperature) below the matrix melt temperature and below that which might adversely affect the agent in any manner will shorten the wash time. For most polymers and agent wash temperatures in the range of about 50C to about 60C may be used advantageously. For both types of devices it is desirable to carry out the wash with agitation to ensure good clearance of the released agent from the exterior of the device.
Although any degree of prewashing will improve the release kinetics of the device, it is desirable to remove active agent from a layer which represents at least about of the total thickness or diameter of the device. Usually the thickness of the layer will comprise about 5% to about 25% of the overall thickness or diameter. It should be understood that in most devices the layer appears at both sides or both edges of the device and that the above percentages relate to only a single appearance of the layer. In other words in a spherical device the layer would appear at both ends of a diameter and thus the total diametrical drug depleted portion of the device would represent at least about of the entire diameter.
EXAMPLES The invention process and the improvement in release kinetics realized by using it are further illustrated by the following examples.
Example 1 A. A monolithic diffusion device such as might be used to dispense a drug intrauterinely is made by mixing 20 parts progesterone (5-10 micron particle size) into a methylene chloride solution of 80 parts ethylenevinyl acetate copolymer (the drug loading is approximately 20% by volume). This mixture is cast into a 0.2 cm thick sheet from which a rectangular body having a total surface area of 1 cm is cut. This rectangular body is placed in a simulated uterine environment where it releases progesterone by diffusion. This release is monitored, the plot of which is shown in FIG. 3. As seen in FIG. 3 the initial release rate of progesterone is in the neighborhood of 150 ,ug/day and drops off rapidly during the first 100 days to about 40 ,ug/day after which the release curve slowly and continuously declines until the solid progesterone is exhausted.
B. Three rectangular bodies of a progesterone/ethylene-vinyl acetate copolymer dispersion are prepared as in A. Each is washed in water at 50C; the first until a drug free surface layer 0.020 cm thick is formed; the second until a drug free layer 0.033 cm thick is formed;
and the third until a drug free layer 0.047 cm thick is formed. Each device is then placed in the simulated uterine environment as described in A and the progesterone release therefrom is monitored and plotted, the plots of which are shown in FIG. 4. As shown by these plots the initial release rate relative to the unwashed device is decreased respectively by about 30%, 60% and in the washed devices. Also the release rate during the major portion of the devices lifetime (ca. days to 500 days) is not significantly decreased by the washing.
Example 2 A. A device identical with that of Example 1A and two other devices identical to the same except in drug loading (one contained half the amount of progesterone and the other contained double the amount of progesterone) are prepared and tested as in Example lA. Their release plots are illustrated in FIG. 5.
B. Three devices identical to those ofA are prepared and prewashed in water at 50C until a 0.047 cm thick drug-free layer is formed in each. These washed devices are then tested as in Example lA. Their release plots are shown in FIG. 6.
As is readily seen by comparing FIGS. 5 and 6 the washing eliminated the initial burst in the progesterone release while not significantly affecting the release rate over the bulk of each devices lifetime.
Example 3 A. An osmotic bursting device such as might be used to dispense drug to the eye is made by mixing 30 parts pilocarpine nitrate with 70 parts of ethylene/vinyl acetate copolymer on a laboratory rubber mill. The well dispersed mixture which contains pilocarpine nitrate particles with an average diameter of between 1 and 10 microns is then pressed into a flat film 500 microns thick from which an ellipse shaped body 13.5 mm by 6.5 mm is cut. This body is placed in simulated lachrymal fluid at 37C where it releases pilocarpine nitrate by an osmotic bursting mechanism. This release is monitored, the plot of which is shown in FIG. 9. As seen in FIG. 9 the initial pilocarpine nitrate release rate is about 175pg/hour and drops off rapidly during the first 25 hours to about 25 ug/hour.
B. Five devices identical to those of A are prepared and soaked in water at 37C for 15, 30, 60 and minutes and 24 hours respectively. Each device is then tested as in A. Their pilocarpine nitrate release plots are shown in FIG. 10. As shown by these plots the washing decreases the initial release rate by about 20%, 40%, 50%, and 90% respectively. Also, there is little variation in release rate between the unwashed and washed devices after 25 hours.
Example 4 Osmotic bursting ocular inserts are made by dispersing 30 parts tetracycline hycrochloride in 70 parts ethylene/vinyl acetate copolymer (Elvax 220) on a rubber mill, melt pressing the dispersion into a flat film 500 microns thick and cutting 13.5 mm X 5.8 mm ellipses therefrom. Individual ellipses are washed, 0, 15, 30, 60 and 120 minutes respectively, in water at 50C, dried and then placed in simulated lachrymal fluid. The average tetracycline hydrochloride release over the first-7 hours of release is respectively 26, l8, l7, l2 and 9 ug/hour.
Example inserts were made and tested as in Example 4 except that a different ethylene/vinyl acetate copolymer (Elvax 40) was used. The average tetracycline hydrochloride release over the first 7 hoursis, respectively, 25,15, 12, 9 and 6 ug/hour.
Various modifications of the invention process will be obvious to those of ordinary skill in the active agent formulations art. Such modifications are intended to be within the scope and spirit of the following claims.
1. Method for substantially reducing the initial burst of active agent release from a monolithic active agent delivery device when said device is placed in its environment of use, said device comprising a shaped body of a dispersion of particulate active agent within a polymer matrix comprising prior to placing said shaped body in said environment, removing the particulate agent from the exterior surface of said body to form an agent depleted layer of polymer matrix voided by such removal of particulate active agent, the thickness of said layer being at least about 5% of the overall thickness of the body.
2. The method of claim 1 wherein said removing is done by washing the body in a liquid which is inert relative to said polymer matrix.
3. The method of claim 2 wherein said liquid is water.
4. The method of claim 2 wherein said device is a diffusion type device and said washing is carried out at an elevated temperature at which diffusion of the agent from the matrix is enhanced.
5. The method of claim 2 wherein the polymer matrix is an ethylene/vinyl acetate copolymer and the washing is carried out at about 50C to about 60C.
6. The method of claim 2 wherein the device is an osmotic bursting type device and the washing is carried out at an elevated temperature at which imbibition of said liquid by the active agent is enhanced.
7. The method of claim 1 wherein the thickness of the layer is about 5% to 25% of the overall thickness of the body.
8. In a process for making a monolithic drug delivery device comprising a dispersion of solid particulate drug in a polymer matrix comprising the steps of forming a dispersion of the solid particulate drug within said matrix and forming the dispersion into a shaped body adapted for placement in the environment of use of the device, the improvement comprising the additional step of removing the solid particulate drug from the surface of said body to form a drug depleted layer of polymer matrix voided by the removal of the particulate solid drug therefrom, the thickness of said layer being at least about 5% of the overall thickness of said body.
9. The improvement of claim 8 in which the thickness of said layer is about 5% to about 25% of the overall thickness of the body.
10. The improvement of claim 8 wherein said removing is done by washing the body in a liquid which is inert relative to the polymer matrix.
11. The improvement of claim 10 wherein the liquid is water.
12. The improvement of claim 10 wherein the device is a diffusion type device and said washing is carried out at an elevated temperatureat which diffusion of the drug from the matrix is enhanced.
13. The improvement of claim 12 wherein the polymer matrix is made of an ethylene/vinyl acetate copolymer and the elevated temperature is from about 50C to about C.
14. The improvement of claim 10 wherein the device is an osmotic bursting type device and the washing is carried out at an elevated temperature at which the imbibition of liquid by the active agent is enhanced.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3402240 *||25 Jun 1957||17 Sep 1968||Pfizer & Co C||Medicinal tablet and process of making same|
|US3700380 *||1 Oct 1970||24 Oct 1972||Tecna Corp||Surface or lining compatible with blood or other tissue|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4145408 *||31 Oct 1977||20 Mar 1979||The Procter & Gamble Company||Controlled release article|
|US4156604 *||15 Sep 1978||29 May 1979||Minnesota Mining And Manufacturing Company||Controlled delivery of corrosion inhibitors for silver recovery cartridges|
|US4177256 *||29 Nov 1977||4 Dec 1979||Alza Corporation||Osmotic bursting drug delivery device|
|US4190642 *||11 May 1979||26 Feb 1980||Alza Corporation||Ocular therapeutic system for dispensing a medication formulation|
|US4267138 *||19 Sep 1977||12 May 1981||Richter Gedeon Vegyeszeti Gyar Rt.||Coating ensuring a controlled release of active ingredients of biologically active compositions, particularly pharmaceutical compositions and a process for preparation of biologically active compositions ensuring controlled release of active ingredients|
|US4304765 *||14 Oct 1980||8 Dec 1981||Alza Corporation||Ocular insert housing steroid in two different therapeutic forms|
|US4333850 *||15 Jun 1979||8 Jun 1982||Borg-Warner Corporation||Filled polymer composition for automatic addition of a corrosion inhibitor to a coolant system|
|US4432964 *||27 Dec 1982||21 Feb 1984||Alza Corporation||Topical composition containing steroid in two forms released independently from polymeric carrier|
|US4478818 *||5 Jan 1984||23 Oct 1984||Alza Corporation||Ocular preparation housing steroid in two different therapeutic forms|
|US4557925 *||5 Sep 1984||10 Dec 1985||Ab Ferrosan||Membrane-coated sustained-release tablets and method|
|US4564364 *||26 May 1983||14 Jan 1986||Alza Corporation||Active agent dispenser|
|US4629619 *||19 Sep 1985||16 Dec 1986||Ab Ferrosan||Membrane-coated sustained-release tablets and method|
|US4629620 *||19 Sep 1985||16 Dec 1986||Ab Ferrosan||Membrane-coated sustained-release tablets and method|
|US4704282 *||29 Jun 1984||3 Nov 1987||Alza Corporation||Transdermal therapeutic system having improved delivery characteristics|
|US4725439 *||13 Jan 1986||16 Feb 1988||Alza Corporation||Transdermal drug delivery device|
|US4761289 *||10 Oct 1986||2 Aug 1988||International Minerals & Chemical Corp.||Sustained release implant and method for preparing same|
|US4781924 *||9 Nov 1987||1 Nov 1988||Alza Corporation||Transdermal drug delivery device|
|US4837027 *||9 Aug 1988||6 Jun 1989||Alza Corporation||Transdermal drug delivery device|
|US4874366 *||19 Dec 1988||17 Oct 1989||Baxter Internatiional Inc.||Housing enabling passive mixing of a beneficial agent with a diluent|
|US4898733 *||4 Nov 1985||6 Feb 1990||International Minerals & Chemical Corp.||Layered, compression molded device for the sustained release of a beneficial agent|
|US4908027 *||12 Sep 1986||13 Mar 1990||Alza Corporation||Subsaturated transdermal therapeutic system having improved release characteristics|
|US4917895 *||14 Jul 1988||17 Apr 1990||Alza Corporation||Transdermal drug delivery device|
|US4923607 *||30 Nov 1987||8 May 1990||Nitto Denko Corporation||Membrane containing a liquid active substance and process for the production of same|
|US4978537 *||19 Apr 1989||18 Dec 1990||Wm. Wrigley Jr. Company||Gradual release structures for chewing gum|
|US5024657 *||4 May 1990||18 Jun 1991||Baxter International Inc.||Drug delivery apparatus and method preventing local and systemic toxicity|
|US5071656 *||14 Nov 1988||10 Dec 1991||Alza Corporation||Delayed onset transdermal delivery device|
|US5091186 *||15 Aug 1989||25 Feb 1992||Cygnus Therapeutic Systems||Biphasic transdermal drug delivery device|
|US5108762 *||30 Oct 1990||28 Apr 1992||Wm. Wrigley Jr. Company||Gradual release structures for chewing gum|
|US5124157 *||18 Aug 1989||23 Jun 1992||Cygnus Therapeutic Systems||Method and device for administering dexmedetomidine transdermally|
|US5128155 *||20 Dec 1990||7 Jul 1992||Wm. Wrigley Jr. Company||Flavor releasing structures for chewing gum|
|US5141750 *||14 Nov 1988||25 Aug 1992||Alza Corporation||Delayed onset transdermal delivery device|
|US5154939 *||8 Nov 1991||13 Oct 1992||Wm. Wrigley Jr. Company||Use of salt to improve extrusion encapsulation of chewing gum ingredients|
|US5165944 *||18 Oct 1991||24 Nov 1992||Wm. Wrigley Jr. Company||Gradual release structures for chewing gum|
|US5198251 *||16 Dec 1991||30 Mar 1993||Wm. Wrigley Jr. Company||Gradual release structures for chewing gum|
|US5229148 *||20 Feb 1992||20 Jul 1993||Wm. Wrigley Jr. Company||Method of combining active ingredients with polyvinyl acetates|
|US5284660 *||21 Aug 1992||8 Feb 1994||Alza Corporation||Delayed onset transdermal delivery device|
|US5342623 *||18 Jun 1993||30 Aug 1994||Alza Corporation||Subsaturated transdermal therapeutic system having improved release characteristics|
|US5364627 *||21 Jul 1992||15 Nov 1994||Wm. Wrigley Jr. Company||Gradual release structures made from fiber spinning techniques|
|US5508038 *||16 Apr 1990||16 Apr 1996||Alza Corporation||Polyisobutylene adhesives for transdermal devices|
|US5564439 *||27 Dec 1994||15 Oct 1996||George J. Picha||Infusion device for soft tissue|
|US5706807 *||11 Oct 1996||13 Jan 1998||Applied Medical Research||Sensor device covered with foam membrane|
|US5798065 *||2 Oct 1997||25 Aug 1998||George J. Picha||Collagen disruptive surface morphology for implants|
|US5819742 *||30 Oct 1997||13 Oct 1998||Family Health International||Vaginal device for preventing conception or the transmission of sexually transmitted diseases, or both|
|US5853758 *||10 Jul 1996||29 Dec 1998||Pfizer Inc.||Preparation of tablets of increased strength|
|US5962011 *||24 Jun 1997||5 Oct 1999||Schering-Plough Healthcare Products, Inc.||Device for delivery of dermatological ingredients|
|US6110500 *||25 Mar 1998||29 Aug 2000||Temple University||Coated tablet with long term parabolic and zero-order release kinetics|
|US6126956 *||22 Dec 1998||3 Oct 2000||Axxia Technologies||Subcutaneous implant|
|US6130200 *||18 Dec 1997||10 Oct 2000||Alza Corporation||Gel composition and methods|
|US6331311||18 Dec 1997||18 Dec 2001||Alza Corporation||Injectable depot gel composition and method of preparing the composition|
|US6468961||13 Jul 2000||22 Oct 2002||Alza Corporation||Gel composition and methods|
|US6673767||21 Mar 2000||6 Jan 2004||Alza Corporation||Gel composition and methods|
|US7118376 *||14 Mar 2001||10 Oct 2006||Coll Partners Ltd.||System for the controlled delivery of an active material to a dental site|
|US7829109||9 Nov 2010||Durect Corporation||Catheter injectable depot compositions and uses thereof|
|US8252303||14 Nov 2002||28 Aug 2012||Durect Corporation||Injectable depot compositions and uses thereof|
|US8278330||27 Sep 2010||2 Oct 2012||Durect Corporation||Short duration depot formulations|
|US8287277||16 Oct 2012||Colldent V.A. Ltd.||Reshapable device for fixation at a dental site|
|US8303609 *||28 Sep 2001||6 Nov 2012||Cordis Corporation||Coated medical devices|
|US8501215||28 Jul 2003||6 Aug 2013||Guohua Chen||Injectable multimodal polymer depot compositions and uses thereof|
|US8685296 *||10 May 2011||1 Apr 2014||Allergan, Inc.||Porogen compositions, method of making and uses|
|US8852623 *||15 Jun 2012||7 Oct 2014||Titan Pharmaceuticals, Inc.||Implantable polymeric device for sustained release of dopamine agonist|
|US9138308||2 Aug 2012||22 Sep 2015||Apollo Endosurgery, Inc.||Mucosal tissue adhesion via textured surface|
|US9205577 *||28 Sep 2012||8 Dec 2015||Allergan, Inc.||Porogen compositions, methods of making and uses|
|US9278163||3 Oct 2014||8 Mar 2016||Titan Pharmaceuticals, Inc.||Implantable polymeric device for sustained release of dopamine agonist|
|US20030044467 *||19 Aug 2002||6 Mar 2003||Brodbeck Kevin J.||Gel composition and methods|
|US20030157178 *||14 Nov 2002||21 Aug 2003||Guohua Chen||Injectable depot composition|
|US20030165792 *||14 Mar 2001||4 Sep 2003||Ahron Jodaikin||System for the controlled delivery of an active material to a dental site|
|US20030211974 *||4 Jun 2003||13 Nov 2003||Brodbeck Kevin J.||Gel composition and methods|
|US20050175959 *||13 Dec 2004||11 Aug 2005||Coll Partners Ltd.||System for the controlled delivery of an active material to a dental site|
|US20060013879 *||19 Aug 2002||19 Jan 2006||Brodbeck Kevin J||Gel composition and methods|
|US20080026031 *||8 May 2007||31 Jan 2008||Titan Pharmaceuticals, Inc.||Implantable polymeric device for sustained release of buprenorphine|
|US20080311171 *||12 May 2008||18 Dec 2008||Patel Rajesh A||Implantable polymeric device for sustained release of dopamine agonist|
|US20110104635 *||5 May 2011||Coll Partners Ltd.||Reshapable device for fixation at a dental site|
|US20110129516 *||2 Jun 2011||Aton Pharma, Inc.||Ocular drug delivery devices|
|US20110278755 *||17 Nov 2011||Allergan, Inc.||Porogen compositions, method of making and uses|
|US20120258161 *||15 Jun 2012||11 Oct 2012||Patel Rajesh A||Implantable polymeric device for sustained release of dopamine agonist|
|US20130032962 *||7 Feb 2013||Allergan, Inc.||Porogen compositions, methods of making and uses|
|USRE39588 *||31 Oct 1990||24 Apr 2007||Alza Corporation||Transdermal drug delivery device|
|DE3743945A1 *||23 Dec 1987||9 Mar 1989||Lohmann Gmbh & Co Kg||Vorrichtung zur abgabe von stoffen, verfahren zu ihrer herstellung sowie ihre verwendung|
|EP0127282A2 *||26 Mar 1984||5 Dec 1984||Alza Corporation||Improved active agent dispenser|
|EP0249343A1 *||14 May 1987||16 Dec 1987||Alza Corporation||Moisture activation of transdermal drug delivery system|
|EP0729324A1 *||9 Nov 1994||4 Sep 1996||Oculex Pharmaceuticals, Inc.||Biocompatible ocular implants|
|EP0887074A2 *||23 Jun 1998||30 Dec 1998||Hoechst Marion Roussel||Intravaginal drug delivery device|
|WO1985002408A1 *||20 Nov 1984||6 Jun 1985||Exxon Research & Engineering Company||Polymer article of manufacture|
|WO1986003416A1 *||29 Nov 1985||19 Jun 1986||Baxter Travenol Laboratories, Inc.||Drug delivery apparatus preventing local and systemic toxicity|
|WO1990012511A1 *||26 Jan 1990||1 Nov 1990||Wm. Wrigley Jr. Company||Gradual release structures for chewing gum|
|U.S. Classification||264/49, 264/233, 604/57, 264/109, 424/486, 604/523, 128/832, 264/344, 424/469|
|International Classification||A61P31/00, A61K47/32, A61K9/00, A61K31/65, A61P5/00, A61K9/70, A61K9/26, A61K38/22|
|Cooperative Classification||A61K9/0039, A61K9/0051, A61K9/0004|
|European Classification||A61K9/00L4, A61K9/00M8D, A61K9/00M16B|